Key facts
- This page summarizes Kathryn A. Tesija's Form 4 filing for CLOROX CO /DE/ (CLX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Oct 2024, 18:37.
Kathryn A. Tesija - 30 Sep 2024 Form 4 Insider Report for CLOROX CO /DE/ (CLX)
- Reporting relationship
- Director
- Issuer ticker
- CLX
- Reported as of
- 30 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Oct 2024, 18:37:06 UTC
- Prior SEC filing
- 02 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- By Cheryl Brice, Attorney-in-Fact for
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Kathryn A. Tesija filed Form 4 for CLOROX CO /DE/ (CLX) on 02 Oct 2024.
Change
- Previous filing in this sequence was filed on 02 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLX
transaction
Derivative
Deferred Stock Units
Award
- Transaction value
- $0
- Shares
- +50
- Change %
- +0.77%
- Price
- $0.000000
- Shares after
- 6,602
- Date
- 30 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50
- Exercise price
- Footnotes
- F1, F2, F3
CLX
transaction
Derivative
Deferred Stock Units
Award
- Transaction value
- $0
- Shares
- +161
- Change %
- +2.4%
- Price
- $0.000000
- Shares after
- 6,763
- Date
- 30 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 161
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
1-for-1
Footnote F2
Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.
Footnote F3
The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.
Footnote F4
Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.